Table 3 from Clinical Validity of FoundationOne Liquid CDx for Detection of BRAFV600E in Colorectal Cancer

Key Points

• Concordance analysis reveals the detection accuracy of FoundationOne Liquid CDx for BRAF V600E in colorectal cancer.
• High concordance rates indicate it is a viable option for BRAF V600E testing in clinical settings.
• The methodology used allows for an effective comparison against traditional testing methods.
• Findings support the integration of FoundationOne Liquid CDx in routine colorectal cancer diagnostics.